The Effects of Duloxetine on Pain and Hip Function after Total Knee Arthroplasty: a Randomized Controlled Trial.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000033910

Enrollment

Unknown

Registered

2020-06-16

Start date

2020-06-15

Completion date

Unknown

Last updated

2020-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total knee arthroplasty

Interventions

Group B:Placebo

Group A:Duloxetine

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patients to be treated with total knee arthroplasty; 2. Patients aged 18-85; 3. Patients who sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Preoperative diagnosis of anxiety and depression patients (Hamilton Depression Scale score more than 20); 2. Patients with duloxetine allergy; 3. Patients who have taken duloxetine before; 4. Patients with high preoperative inflammatory factor (CRP > 20mg / L); 5. Patients with abnormal platelet function, coagulation function and liver and kidney function before operation.

Design outcomes

Primary

Measure	Time frame
VAS pain score;Postoperative morphine consumption;	—

Secondary

Measure	Time frame
Timed Up & Go Test;Range of motion;Knee society score;Womac score;Hamilton Depression Scale;SF-12;	—

Countries

China

Contacts

Public ContactZongke Zhou

West China Hospital of Sichuan University

zhouzongke@scu.edu.cn+86 18980601028

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026